CNY 75.50
−2.35%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenCNY 68.49
From 52W high−18.62%
Volume11.00M
Market capCNY 18.65B
P/E (TTM)669.2x
P/S (TTM)15.0x
Div yield—
Key dataSep 18, 2026
Open
CNY 68.49
From 52W high
−18.62%
Volume
11.00M
Market cap
CNY 18.65B
ValuationView details →
P/E (Fwd)
125.9x
EV/EBITDA
85.7x
P/E (TTM)
669.2x
RSI (14)
52.1
MomentumView details →
1D Return
−2.35%
YTD Return
—
Similar companies
Latest newsMore news →
CanSino Biologics reported its first-half 2026 results, with revenue of 550 million yuan, up 43.81% year-on-year, and a net loss attributable to shareholders of 720,800 yuan, compared with a loss of 13.4854 million yuan in the same period of 2025.24d agoCanSino Biologics announced it is advancing research and development of mRNA vaccines for indications including glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as InVivoCAR-related therapies, all currently in early stages.25d ago